Anticardiolipin antibodies and thrombosis

Area of Science:

• Immunology
• Hematology
• Vascular Medicine

Background:

• Anticardiolipin antibodies (ACLAs) are a significant acquired risk factor for thrombosis.
• The exact mechanisms by which ACLAs induce a hypercoagulable state are still under investigation.
• ACLAs are associated with various thrombotic events, categorized into four syndrome types.

Purpose of the Study:

• To highlight the strong association between anticardiolipin antibodies and thrombosis.
• To emphasize the importance of assessing ACLAs in individuals with unexplained thrombotic events.
• To discuss the clinical significance of defining ACLA-associated syndrome types for treatment.

Main Methods:

• Review of existing literature on anticardiolipin antibodies and thrombosis.
• Classification of thrombotic events associated with ACLAs into syndrome types (I-IV).
• Discussion of diagnostic considerations, including assessment of IgG, IgA, and IgM idiotypes.

Main Results:

• Anticardiolipin antibodies are the most common acquired blood protein defect linked to thrombosis.
• Common thrombotic events include deep vein thrombosis/pulmonary embolus (Type I), arterial thrombosis (Type II), and cerebrovascular/retinal thrombosis (Type III), with mixed presentations (Type IV).
• The frequency of ACLAs in both arterial and venous thrombosis warrants their investigation in unexplained cases.

Conclusions:

• Anticardiolipin antibodies should be investigated in patients presenting with unexplained thrombosis.
• Assessment of all three idiotypes (IgG, IgA, IgM) is recommended.
• Defining the specific syndrome type (I-IV) is critical for determining appropriate anticoagulant therapy, both immediate and long-term.